Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well, of you can't and will be hacked via installed apps.
That's not the point of a phone w/ physical off-switches,
i.e. they serve you to disable sensors (mic, camera, ..) to ensure basic phone operations and privacy while these are switched off.
that idea is not new at all
this has nothing to do w/ this company, since they probably won't deliver as usual - as some say, it highly likely might be a scam.
there are thousands of stocks out there .. :)
reversal not confirmed yet, quite boring trading days.
At least the 0.30'ish bottom has held.
A 1:15 RS & halving the AS leads to an AS increase of 7.5 multiple!
Then the Total's F-4 transfer discloses again that about $13M notes are due on 15th of May and will be highly likely being converted. This will also allow Temasek to convert their notes as far as I know.
After the big cleanup and RS, this may have a chance. Until then it probably will slide. We will see.
PS: Some last minute sweetener deal has been arranged w/ those $10M taken from the ER 'pre-release', causing the law-suits now.
The 'Sheikh' mentioned a buy back target of $0.40, drop of course due to upcoming dilution. I guess this price has been calculated in a thread here b4 - roughly a 40% drop.
Further more, the RS might still be debated by company in case they like to be accessible by some (foreign) brokers and in case they like to perform the uplisting.
Thank you all for your great posts.
I am watching this development and may re-enter after dilution,
or if I smell good news of course. We never know.
In the very end, it all may not matter, assuming success.
support re-tested, reversal candle,
see https://www.tradingview.com/x/bNcIJKll/
(post copied & merged from other board, johnny007 @ stockhouse.com, thank you)
My chart is shown as linked above, RT market data via tradeview and the only cross down, aka dead cross, I can see is on 4/24 50ma x 20ma, not the golden 200ma Sir!
Sure, that was bad, hence we are back at the channel bottom.
I propose nothing to anybody here, just inform you that I see a reversal play going on right now,
since this is the usual channel trading. If you use charts, well - then you should know.
Fundamentally the company's balance sheet is of course quite weak and this is only played due to anticipation that their liquid biopsy testing receives more insurance contracts and/or a buyout.
But hey, 4Q16 was even profitable .. a little bit, that was a great sign of execution, besides the liquidity issues they had. I do expect a great turnaround in 2017.
On another positive note, .30 held today and it does prove support. Especially that over 100k trade, as you like watching the tape.
Yes, it is too early to read the indicators and I play this merely on it's strong support range .29 - .31 for the channel surfing and maybe even good news on the way up.
Further, I have marked 3 occasions in the chart w/ same daily candlestick and the last one had a short 50ma x 20ma 'dead' cross as well, those don't last long w/ this stock's trade. Price and channel bound.
With this .30'ish support we should at least expect a 200ma snap-back, happens quite often. I trade this not only for the bounce, but in the hope that we receive that insurance deal update as anticipated on the way up .. we will see.
TSX:GEN, aka GEN on Toronto Stock Exchange as mentioned in the header of this board.
Welcome to the GeneNews board.
I was missing an opportunity to discuss this company w/o bashing et al., so I simply created this board.
As we go, news and fundamentals will be added.
Today it almost touched down on its channel low of CAD 0.29, i.e. CAD 0.295. The low is its typical support line.
After issuing the ER, company is expected to release material news about insurance coverage, which hasn't been done yet.
Looking forward to a fruitful discussion.
I see, makes sense. So it might be about funding the big one 300 pt mono trial to really cut it and make sure progress.
Well, I would prefer following this path. Dilution will happen anyways, so far it happened sliced by slice.
It is much simpler to measure company performance w/ mono trial it seems, since more patients are eager to really want to participate. Heck, if some are not qualifying after screening, but are still CCR5 (sic) - just give them the drug on a side arm for PR reasons. I could see so many benefits here.
While this trial would be ongoing, they could slowly continue the difficult HART combo enrollment process, which will eventually be complete.
This drama shows us that there are no short cuts.
Maybe we should call Tony to discuss this, AFAIK they already thought about it .. but not yet willing to admit this is the wrong way.
A Gilead partnership funding should be feasible as well, giving them priority in a buyout process.
Maybe the latter didn't work out yet also just because of the slow pace of progress.
Conclusion, a fast track mono path is the way to go. Combo is too slow for this biz.
Sorry for being repetitive ..
Last CC sounded like mono enrollment and treatment is the actual easy way, compared to all those HART salvage issues. Tony acknowledged that.
Now my question is, why can't they simply follow the most logical path forward and kick-off mono first and followup with HART enrollment after at least 100pt mono are enrolled?
This would allow to start the mono trials already with those 100 pt. Such a phase shift, i.e. phasing 100pt for mono in might be very beneficial anyways for ongoing adjustments.
I feel CYDY mgmt is quite stubborn here blocking progress this way.
10-Q reflection: PO + Delay
No cash left, the usual raise, no surprise,
hopefully at $0.75/sh again.
The real bad: Stretching the timeline again.
2017 March presentation already delayed program 1Q17 -> 2Q17 etc.
Now they say that Combo enrollment is complete 2Q17, where it was expected to have the results!
Further more, Mono enrollment is now expected to be completed 4Q17 where the Combo trial requires the 100pt of the Mono trial for safety. They don't even mention the 100pt enrollment and their safety data, but only say some patients were enrolled in Dec 2016 already. For me, that is the real bummer and could delay the whole combo trial results towards 4Q17, if not later.
EDIT: Since they were just mostly enrolling, I also have to ask how they burned the $2.17M per month?
Thoughts?
Orthopaedics, oh dear - they should have hired one HIV specialist of course. But I assume that is progress from hiring a mechanics PhD. Sorry, couldn't resists.
I also hope Pro 140 becomes success, but I am puzzled about the inefficiency of and lack of clarity from this management team.
Fascinating.
The king is dead, all hail the king.
Next: McAfee will be dissed and declared useless and all hail Ladd :)
Who needs a real biz case when you can have stories?
Oh wait, maybe that is the biz.
No Sentinel
No D-Vasive
No Daemonsaw
No Clear Sky
No Bitcoin Pool
No PH mining capacity
No phone?
No nothing?
When even the initiator sues his genies after letting them out of their little bottles to get together for a show, because they performed so well and even cheated on their master :)
the debt/equity conversion price was contractual .., and the numbers of shares they got as well.
Some day, maybe some day - Amyris may have solved the toxic financing problem. Fully digested its history, if and when mastering her future being profitable.
Might be even better new CFO gets the sledgehammer and solves the convertibles all at once with a concluding RS. Better than this seemingly never ending bleeding.
Good night and good luck.
I validated "the Sheikh's" pics months ago and they were almost flawless, big KUDOS to him.
Lately he seems to have left this path of very high accuracy?
Seeing a RTTR watchlist recommendation and TXMD turnaround claim based on only labeling issues, where Andy Biotech and AF in Dec 2016 already claimed that the data might not be sufficient, see
.$TXMD failed —https://t.co/NJ6J84J4i9
— Adam Feuerstein ✡️ (@adamfeuerstein) December 6, 2016
Spider, you are not becoming bullish on your old days? :)
The conversion price for many equity financings in 2016 was $0.50/sh:
2016-08-19 D $2.9M, Warrants for 5M shares, strike $0.50 to Ginkgo Bioworks, 10-Q 3Q16 p54
2016-11-01 8-K Guanfu 10% p.a. $25M Credit Facility, optionally being payed back in shares
2016-11-01 8-K 10M shares $5.725M @ $0.50 with Nenter, also see 2016-11-30 D, 2016-12-23 S-3 and 2017-01-10 424b3
Ch11 filed. They would have sold whole company to Ameri100 incl. debt obligations of course, if they still would have been willing to buy.
Instead, they have a stalking horse bid at $50M for their remaining NA and India assets only.
Adding the DIP loan, $29M WF + $41M WF-DIP = $70M would need to be matched to pay off both. However, what would be left to common SH after even NA assets are sold?
Only value would be a complete buyout of company, i.e. paying SH cash or shares of buyer.
Further, NYSE may delist CBR now, since they usually don't hold BK companies. This would make them far less attractive to a buyout used for uplisting.
And yes, Ameri100 is highly likely out as stated above, otherwise BK would not have been utilized. Cheap asset sales ahead.
are they now a late filer for the 10-K?
I have read that they are an 'Accelerated Filer' and therefor the 10-K should have been out on 3/15. They also haven't filed an NT-10K.
In case the public float is less than $75M they could file as an 'Non-accelerated Filer' due 3/31. This date has passed by now as well. Therefor I am either missing something here or they are now a late filer and have 6 month to file before next sanctions may hit.
Ideas?
according to German BK law, parent cannot being drawn into this BK case, see https://content.next.westlaw.com/8-566-7187?__lrTS=20170401203024510&transitionType=Default&contextData=(sc.Default)&firstPage=true&bhcp=1
this explains Friday trade, no big plunge and even a very well volume supported rise at closing.
German Ciber companies file for insolvency
http://www.reuters.com/article/idUSL5N1H80LP
Now I would love to know whether it is possible for CBR parent to stay out of BK while the German subsidies file for BK.
Since the parents to enjoy revenue from the subsidies and are on the common balance sheet, I would assume that the parent must pay for all liabilities first. This implies that the subsidies can only file for BK if CBR parent does.
Please help elucidating this issue, thank you.
2017 March Presentation p20, while stretching the timeline a bit saying 2H17 (2Q17) instead of 1Q17, they are still on track.
Combo primary and the Mono-Part1(100 pt safety) is targeted together for 2Q17. Also 2 publications for ASM. Hopefully they have enrolled much more than one patient for mono so far. Maybe they will disclose some more details at the next CC. A little eastern egg for all of us, if lucky :)
BTD + ODD now expected in 2H17 for Mono BLA, probably, using existing data. Sensible.
April - June 2017 might deliver some significant event according to this schedule. After waiting much longer already, this final period seems like a nice hike.
Phase 1 data out, confirming pre-clinical trial safety of MAT2501. I read this may even hint towards efficacy based on the way the drug delivery concept works? Ideas?
Yes, the selling is of course no joke. Temasek wants to get out at any costs, whatever the reasons are.
Then the disbelieve of the OS count:
Convertibles Outstanding
- 2016-12-01 424b5
+ 29.323M equity incentive plans: (i) options 13.801M sh @ $3.62/sh, (ii) restricted stock units to 7.475M sh
+ 14.663M outstanding warrants $0.18/sh
+ 67.223M outstanding convertible promissory notes
= 111.209M w/ 81.89M convertibles
Offering
1- 2016-03-08 ATM $50M via FBR Capital Markets & Co
2- 2016-12-01 424b5 $10M: 5.263M @ $1.90 initial conversion price
3- 2016-12-23 S-3 10M shares for $0.69 $6.9M for conversion/resale, Nenter (Guanfu): Warrant shares at $0.50/sh
3- 2017-01-06 EFFECT 10M shares Nenter/Guanfu
- 2016-12-23 S-3
- 2017-01-10 424B3
- 2016-11-30 273.826M (from S-3)
^^ you need to add at least the 10M shares here, but IMO also most of the above to get to a proper future OS base.
This will lead us to round about, yes, 370M OS.
This is widely know and has to be accepted. It doesn't even include all convertible debt yet. And one must be blind to ignore the toxic financing.
So this is the bear part of my post.
The bullish angle is if company will finally show the world that the turnaround is actually happening, not just in words, but within the financial data filed!
So far, this didn't happen yet - bummer. Costs of revenue were still higher than sales, even though the losses decline.
The remedy is already in the story: Brotas 2.
The quarter Brotas 2 comes online, people hope 4Q17 is the time, no more downtimes due to product change cycles will occur and company is able to materialize production at profitable levels.
The fact that company has moved away from biofuel and reinstated their R&D division for better high margin products is a necessity for the turnaround. Melo's company destruction for years due to his non profitable 'biofuel only' plan has been reverted.
Bottom line: Stock indeed may continue to decline if no appreciation of the profitable turnaround appears before it happens. This is surely an issue of trust, or better lack thereof. Hence 2017 shall be the year, but appreciation may not happen in full before its 10-K filing.
Just my 2 cents